These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
905 related items for PubMed ID: 20060082
1. Efficacy and safety of monthly ibandronate in men with low bone density. Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G. Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082 [Abstract] [Full Text] [Related]
2. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S. Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148 [Abstract] [Full Text] [Related]
8. Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA. J Clin Endocrinol Metab; 2009 Jan; 94(1):171-80. PubMed ID: 18840641 [Abstract] [Full Text] [Related]
9. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study. Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium. Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208 [Abstract] [Full Text] [Related]
10. The effect of monthly ibandronate on bone mineral density and bone turnover markers in patients with haemophilia A and B and increased risk for fracture. Anagnostis P, Vyzantiadis TA, Charizopoulou M, Adamidou F, Karras S, Goulis DG, Karagiannis A, Garipidou V, Vakalopoulou S. Thromb Haemost; 2013 Aug; 110(2):257-63. PubMed ID: 23740140 [Abstract] [Full Text] [Related]
11. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR. J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172 [Abstract] [Full Text] [Related]
12. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY. Clin Rheumatol; 2008 Aug; 27(8):955-60. PubMed ID: 18180976 [Abstract] [Full Text] [Related]
13. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW. J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926 [Abstract] [Full Text] [Related]
14. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327 [Abstract] [Full Text] [Related]
15. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Miller PD, Epstein S, Sedarati F, Reginster JY. Curr Med Res Opin; 2008 Jan; 24(1):207-13. PubMed ID: 18042311 [Abstract] [Full Text] [Related]
16. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Epstein S, Jeglitsch M, McCloskey E. Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464 [Abstract] [Full Text] [Related]
18. Oral weekly ibandronate prevents bone loss in postmenopausal women. Tankó LB, Felsenberg D, Czerwiński E, Burdeska A, Jonkanski I, Hughes C, Christiansen C, Oral Ibandronate Group. J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697 [Abstract] [Full Text] [Related]
19. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. J Bone Miner Res; 2010 Oct; 25(10):2239-50. PubMed ID: 20499357 [Abstract] [Full Text] [Related]
20. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH. Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122 [Abstract] [Full Text] [Related] Page: [Next] [New Search]